(Japanese)

(Japanese)

(Japanese)

Dramatically

Accelerating 

Infectious Disease Research.

Our MPV* and Mylc** cells, produced with regenerative medicine technologies, will solve the shortage of experimental cells for researches on malaria and other infectious diseases, and help researchers accelerate their experiments exponentially.

* We are now providing test

and pilot products and will

start full-scale production in 2020.

** We start to sell this product from 12th Dec in 2019. 

NEWS RELEASE

April 20 ,2020

We are attending COVID-19 Virtual Partnering event to find collaborators to develop solutions

April 14 ,2020

Our activities was introduced on the site of the discover the deep tech startups fighting COVID-19 

March 27,2020

Announcing an ideal human blood cell, Mylc, for coronavirus COVID-19 research

PRODUCT  Video

PRODUCT  LINE-UP

Mpv

immature

red blood-like cells for

Malaria (P.vivax)

research

Mylc

special

myeloid lineage cells for

Dengue and other infectious diseases

© 2019 MiCAN Technologies Inc.

KKVP, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan

​〒615-8245 京都市西京区御陵大原1-36 京大桂ベンチャープラザ